We assume that PGRMC1 overexpression leads to higher dependence on cholesterol and fatty acids of cancer cells due to an alteration of fatty acid metabolism, by enhanced driving of the mevalonate pathway and related synthesis of the isoprenoids geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP) [61, 62], e.g., leading to inhibition of small Rho GTPase prenylation [63]. The gene discussed is PGRMC1; the disease is cancer.